Pharmacokinetic Analysis of Nicotinamide Riboside

NCT02300740 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-02-27

No results posted yet for this study

Summary

Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so far not analyzed.

Conditions

  • Healthy Participants

Interventions

DIETARY_SUPPLEMENT

Nicotinamide riboside

NIAGEN, ChromaDex

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER
  • Aarhus University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300740 on ClinicalTrials.gov